首页> 外文期刊>Science translational medicine >Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome.
【24h】

Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome.

机译:Mecp2突变型小鼠中致命性心律失常的发病机制:对雷特综合征的治疗意义。

获取原文
获取原文并翻译 | 示例
           

摘要

Rett syndrome is a neurodevelopmental disorder typically caused by mutations in methyl-CpG-binding protein 2 (MECP2) in which 26% of deaths are sudden and of unknown cause. To explore the hypothesis that these deaths may be due to cardiac dysfunction, we characterized the electrocardiograms in 379 people with Rett syndrome and found that 18.5% show prolongation of the corrected QT interval (QTc), an indication of a repolarization abnormality that can predispose to the development of an unstable fatal cardiac rhythm. Male mice lacking MeCP2 function, Mecp2(Null/Y), also have prolonged QTc and show increased susceptibility to induced ventricular tachycardia. Female heterozygous null mice, Mecp2(Null/+), show an age-dependent prolongation of QTc associated with ventricular tachycardia and cardiac-related death. Genetic deletion of MeCP2 function in only the nervous system was sufficient to cause long QTc and ventricular tachycardia, implicating neuronally mediated changes to cardiac electrical conduction as a potential cause of ventricular tachycardia in Rett syndrome. The standard therapy for prolonged QTc in Rett syndrome, beta-adrenergic receptor blockers, did not prevent ventricular tachycardia in Mecp2(Null/Y) mice. To determine whether an alternative therapy would be more appropriate, we characterized cardiomyocytes from Mecp2(Null/Y) mice and found increased persistent sodium current, which was normalized when cells were treated with the sodium channel-blocking anti-seizure drug phenytoin. Treatment with phenytoin reduced both QTc and sustained ventricular tachycardia in Mecp2(Null/Y) mice. These results demonstrate that cardiac abnormalities in Rett syndrome are secondary to abnormal nervous system control, which leads to increased persistent sodium current. Our findings suggest that treatment in people with Rett syndrome would be more effective if it targeted the increased persistent sodium current to prevent lethal cardiac arrhythmias.
机译:Rett综合征是一种神经发育疾病,通常是由甲基CpG结合蛋白2(MECP2)突变引起的,其中26%的死亡是突然的且原因不明。为了探究这些死亡可能是由于心脏功能障碍导致的假说,我们对379名患有Rett综合征的人的心电图进行了特征分析,发现18.5%的人表现出校正后的QT间期(QTc)延长,这表明极化倾向异常可能导致不稳定的致命性心律的发展。缺乏MeCP2功能的雄性小鼠Mecp2(Null / Y)的QTc也延长,并且对诱发的室性心动过速的敏感性增加。雌性杂合无效小鼠Mecp2(Null / +)显示与室性心动过速和心脏相关死亡相关的QTc的年龄依赖性延长。 MeCP2功能仅在神经系统中的基因缺失足以引起长时间的QTc和室性心动过速,暗示神经元介导的心脏电传导变化是Rett综合征中室性心动过速的潜在原因。 Rett综合征中延长QTc的标准疗法β-肾上腺素能受体阻滞剂不能预防Mecp2(Null / Y)小鼠的室性心动过速。为了确定替代疗法是否更合适,我们对Mecp2(Null / Y)小鼠的心肌细胞进行了表征,发现持续的钠电流增加,当用钠通道阻滞抗癫痫药苯妥英钠治疗细胞后,钠电流得以正常化。苯妥英钠治疗可降低Mecp2(Null / Y)小鼠的QTc和持续性室性心动过速。这些结果表明,Rett综合征的心脏异常是神经系统控制异常所致,这导致持续的钠电流增加。我们的研究结果表明,如果针对瑞特综合症患者的持续钠电流增加,以预防致命性心律失常,则治疗会更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号